Last reviewed · How we verify

NCT06071728: RESTORE

Restoring Glycocalyx Thickness in Older Adults to Improve Vascular Function

Completed NA Last updated 28 February 2024
What this trial tests

NA trial testing Endocalyx Pro (Microvascular Health Solutions, US Patent Number: 9943572) in Aging in 24 participants. Completed in 31 January 2024.

Timeline
10 October 2022
Primary endpoint
31 December 2023
31 January 2024

Quick facts

Lead sponsorUniversity of Iowa
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment24
Start date10 October 2022
Primary completion31 December 2023
Estimated completion31 January 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Iowa

Who can join

Adults 60 to 85, any sex, with Aging or Vascular Stiffness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The glycocalyx serves as the interface between flowing blood and endothelial cells, the single cell layer that lines blood vessels, and is crucial for normal blood vessel function. Specifically, the glycocalyx protects endothelial cells from oxidative stress and inflammation and enables blood vessel dilation, which is largely dependent on the bioavailability of the vasodilatory molecule nitric oxide. Importantly, glycocalyx thickness decreases with age and is predictive of major adverse cardiovascular events in older adults free of cardiovascular disease. Therefore, interventions aimed at restoring glycocalyx thickness in older adults are desperately needed. Endocalyx Pro is a commercially available glycocalyx precursor supplement, manufactured by Microvascular Health Solutions, designed to 1) repair a damaged glycocalyx, 2) protect against damage to the glycocalyx, and 3) synthesize new glycocalyx components, and has been used to increase glycocalyx thickness in humans. However, no study has tested if glycocalyx thickness restores glycocalyx thickness in older adults and improves blood vessel function. Thus, the purpose of this investigation is to determine if 12-weeks of Endocalyx Pro supplementation alters glycocalyx thickness and blood vessel function in older adults. The investigators will use a camera placed under the tongue to determine glycocalyx thickness. The investigators will measure blood vessel function by measuring brachial artery dilation with ultrasound and arterial stiffness using pressure probes placed on the carotid and femoral artery.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Effect of glycocalyx-targeted therapy on vascular function in older adults: a randomized controlled trial.
    Gimblet CJ, Ernst JW, Bell B, Bos KD, et al · · 2024 · cited 7× · PMID 38722754 · DOI 10.1152/japplphysiol.00150.2024
  2. Sex differences in endothelial glycocalyx thickness and the response to glycocalyx-targeted therapy among older adults.
    Gimblet CJ, Donato AJ, Jalal DI, Pierce GL. · · 2025 · cited 1× · PMID 40526020 · DOI 10.14814/phy2.70428

Verify or expand the search:

Other recruiting trials for Aging

Currently open trials in the same condition.

Other University of Iowa trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06071728.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing